
    
      A prospective, multicentre, non-interventional, non-randomized, non-controlled, single arm,
      post-marketing observational program in patients whom betahistine dihydrochloride (BetasercÂ®)
      tablets were prescribed in the usual manner at the maximal recommended daily dose of 48 mg in
      accordance with the locally approved label. Over a program period physician is free to adjust
      betahistine dihydrochloride dose according to country approved label. Adult outpatients with
      vestibular vertigo who can be treated with betahistine dihydrochloride as per the locally
      approved label will be enrolled in the program. The program consists of an observational
      treatment period (up to 2 months) and a follow-up period (up to 2 months, for evaluation of
      the course of vestibular vertigo after treatment completion).
    
  